Mineralys Therapeutics Inc
MLYS13.570USD
-0.095-0.70%
시장 운영 시간 （ET）시세는 15분 지연됩니다
880.37M시가총액
손실P/E TTM
자세한 내용은 Mineralys Therapeutics Inc 회사
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
회사 정보
종목 코드 MLYS
회사 이름Mineralys Therapeutics Inc
상장일Feb 10, 2023
CEOMr. Jon Congleton
직원 수51
유형Ordinary Share
회계 연도 종료Feb 10
주소150 N. Radnor Chester Road
도시RADNOR
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호19087
전화18883786240
웹사이트https://mineralystx.com/
종목 코드 MLYS
상장일Feb 10, 2023
CEOMr. Jon Congleton
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
678.62K
-2.29%
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
62.70K
-57.38%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Daphne Karydas
Ms. Daphne Karydas
Independent Director
Independent Director
--
--
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Founder, Independent Director
Founder, Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
678.62K
-2.29%
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
62.70K
-57.38%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, Jul 19
마지막 업데이트: Sat, Jul 19
주주
주주 유형
주주
주주
비율
Catalys Pacific, LLC
13.26%
RA Capital Management, LP
9.43%
Samsara BioCapital, LLC
8.71%
SR One Capital Management, LP
4.80%
Capital Research Global Investors
4.45%
Other
59.35%
주주
주주
비율
Catalys Pacific, LLC
13.26%
RA Capital Management, LP
9.43%
Samsara BioCapital, LLC
8.71%
SR One Capital Management, LP
4.80%
Capital Research Global Investors
4.45%
Other
59.35%
주주 유형
주주
비율
Investment Advisor
38.81%
Hedge Fund
23.09%
Venture Capital
22.96%
Investment Advisor/Hedge Fund
16.44%
Individual Investor
1.40%
Research Firm
1.10%
Pension Fund
0.67%
Private Equity
0.61%
Bank and Trust
0.09%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
285
69.20M
106.19%
+10.20M
2025Q1
278
68.91M
105.92%
+7.50M
2024Q4
230
53.93M
108.22%
-5.12M
2024Q3
214
51.53M
103.61%
-6.38M
2024Q2
197
51.29M
104.21%
-4.08M
2024Q1
188
49.20M
100.04%
-4.93M
2023Q4
172
42.00M
101.88%
-1.03M
2023Q3
140
43.25M
105.60%
+16.34M
2023Q2
116
41.91M
102.57%
+17.25M
2023Q1
99
41.30M
101.10%
+30.53M
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Catalys Pacific, LLC
8.64M
13.26%
--
--
Mar 31, 2025
RA Capital Management, LP
6.15M
9.43%
+1.30M
+26.72%
Mar 31, 2025
Samsara BioCapital, LLC
5.67M
8.71%
+600.00K
+11.82%
Mar 31, 2025
SR One Capital Management, LP
3.13M
4.8%
+1.11M
+55.09%
Mar 31, 2025
TCG Crossover Management, LLC
2.47M
3.79%
--
--
Mar 31, 2025
Integral Health Asset Management, LLC
2.30M
3.53%
+1.43M
+162.86%
Mar 31, 2025
HBM Partners AG
2.25M
3.45%
--
--
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
2.20M
3.38%
+266.41K
+13.75%
Mar 31, 2025
Caligan Partners, LP
2.15M
3.3%
+1.14M
+112.60%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Virtus LifeSci Biotech Clinical Trials ETF
0.82%
SPDR S&P Biotech ETF
0.2%
iShares Micro-Cap ETF
0.12%
Direxion Daily S&P Biotech Bull 3X Shares
0.11%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
iShares Biotechnology ETF
0.06%
iShares Russell 2000 Growth ETF
0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
ProShares UltraPro Russell2000
0.02%
더 보기
Virtus LifeSci Biotech Clinical Trials ETF
비율0.82%
SPDR S&P Biotech ETF
비율0.2%
iShares Micro-Cap ETF
비율0.12%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.11%
ProShares Ultra Nasdaq Biotechnology
비율0.1%
Invesco Nasdaq Biotechnology ETF
비율0.1%
iShares Biotechnology ETF
비율0.06%
iShares Russell 2000 Growth ETF
비율0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
비율0.03%
ProShares UltraPro Russell2000
비율0.02%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
